Opportunity Information: Apply for PAR 13 306
Apply for PAR 13 306
- The National Institutes of Health in the environment health income security and social services sector is offering a public funding opportunity titled "Developmental Pharmacology and Toxicology Role of Ontogeny (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.113 Environmental Health 93.859 Biomedical Research and Research Training 93.865 Child Health and Human Development Extramural Research.
- This funding opportunity was created on Aug 7, 2013 and posted on Aug 7, 2013.
- Applicants must submit their applications by Sep 7, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education For profit organizations other than small businesses State governments County governments Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) Special district governments City or township governments Others (see text field entitled Additional Information on Eligibility for clarification) Small businesses Independent school districts Public housing authorities/Indian housing authorities.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Developmental Pharmacology and Toxicology Role of Ontogeny (R01) opportunity (Funding Opportunity Number PAR-13-306) is a discretionary National Institutes of Health (NIH) grant program designed to support investigator-initiated research that explains how normal development (ontogeny) shapes the way drugs work and cause harm in pediatric populations. The central idea is that children are not simply "small adults" from a pharmacology and toxicology standpoint. Instead, the biological systems that govern drug absorption, distribution, metabolism, and excretion, along with drug targets and downstream signaling networks, change substantially from fetal life through adolescence. This FOA encourages multidisciplinary projects that combine basic and translational approaches to understand those age-dependent changes and how they influence both therapeutic response and toxicity.
A major emphasis of the announcement is research on developmental changes in drug-metabolizing enzymes, transporters, receptors, and signaling pathways across distinct developmental windows, including fetal life, infancy, childhood, and adolescence. Applications are expected to focus on how maturation alters drug handling and drug action, and how these changes can lead to differences in efficacy, adverse effects, or susceptibility to toxic exposures at different ages. In practical terms, projects might investigate age-related expression or activity patterns of enzymes and transporters, developmental regulation of receptor systems, or how shifting signaling pathway dynamics alter sensitivity to specific drug classes. The FOA is structured to encourage studies that can help clarify mechanisms behind pediatric variability in drug response and that can ultimately inform safer, more effective dosing and risk assessment for children.
The mechanism is an R01 research project grant, indicating support for substantial, hypothesis-driven research programs rather than small pilot efforts. The opportunity was posted on August 7, 2013, with an original and final closing date of September 7, 2016, and it was archived on October 8, 2016. No cost sharing or matching is required. The program is associated with multiple CFDA numbers reflecting its cross-cutting relevance, including environmental health and biomedical research and training, as well as child health and human development extramural research (93.113, 93.859, and 93.865).
Eligibility is broad and includes a wide range of domestic and non-domestic applicants. Eligible entities include public and private institutions of higher education, nonprofit organizations (including those with and without 501(c)(3) status), for-profit organizations other than small businesses, small businesses, and many levels of government (state, county, city/township, special district, and certain tribal governments). The announcement explicitly includes institutions and organizations that serve specific populations, such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribal Colleges and Universities (TCCUs), and Alaska Native and Native Hawaiian Serving Institutions, among others. Foreign organizations and foreign institutions are eligible to apply, and foreign components of U.S. organizations are permitted consistent with NIH policy, meaning projects may incorporate international expertise or resources where justified.
Overall, this FOA targets research that connects developmental biology to pharmacology and toxicology, with the goal of improving mechanistic understanding of why drug effects and toxicities differ across pediatric life stages. The full announcement was made available through the NIH grants guide at http://grants.nih.gov/grants/guide/pa-files/PAR-13-306.html, and support for access or linking issues was routed through the NIH Office of Extramural Research (OER) webmaster.
Frequently Asked Questions (FAQs)
What is the Developmental Pharmacology and Toxicology Role of Ontogeny (R01) opportunity?
This opportunity is a discretionary National Institutes of Health (NIH) grant program that supports investigator-initiated research to explain how normal development (ontogeny) influences how drugs work and how they may cause harm in pediatric populations.
What is the Funding Opportunity Number (FOA) for this program?
The Funding Opportunity Number is PAR-13-306.
What is the main scientific idea behind this FOA?
The FOA is based on the principle that children are not simply "small adults" in pharmacology and toxicology. Biological systems that control drug absorption, distribution, metabolism, and excretion (and also drug targets and downstream signaling) change substantially from fetal life through adolescence, and those changes can affect both therapeutic response and toxicity.
What types of research does this FOA encourage?
The FOA encourages multidisciplinary projects that combine basic and translational approaches to understand age-dependent developmental changes and how those changes influence drug response and toxicity across pediatric life stages.
What pediatric developmental windows are specifically emphasized?
The announcement emphasizes distinct developmental windows including fetal life, infancy, childhood, and adolescence.
What biological factors are a major emphasis of the announcement?
A major emphasis is research on developmental changes in drug-metabolizing enzymes, transporters, receptors, and signaling pathways across pediatric development.
What kinds of drug-related processes are within the scope of this FOA?
Research within scope includes how maturation affects drug absorption, distribution, metabolism, and excretion, as well as how developmental changes affect drug targets and downstream signaling networks that shape drug action and toxicity.
What outcomes or impacts is this research expected to inform?
Projects are expected to help clarify mechanisms behind pediatric variability in drug response and, ultimately, inform safer and more effective dosing and risk assessment for children.
What are examples of topics or approaches that might fit this FOA?
Based on the announcement, example directions include investigating age-related expression or activity patterns of enzymes and transporters, developmental regulation of receptor systems, or how changes in signaling pathway dynamics alter sensitivity to specific drug classes.
What grant mechanism is used for this opportunity?
The mechanism is an R01 research project grant.
What does the R01 mechanism imply about the type of project being supported?
An R01 indicates support for substantial, hypothesis-driven research programs rather than small pilot efforts.
When was this opportunity posted?
It was posted on August 7, 2013.
What were the closing dates for the opportunity?
The original and final closing date was September 7, 2016.
Is this funding opportunity still active?
No. The FOA was archived on October 8, 2016.
Is cost sharing or matching required?
No cost sharing or matching is required.
Which CFDA numbers are associated with this program?
The program is associated with multiple CFDA numbers: 93.113, 93.859, and 93.865.
Who is eligible to apply?
Eligibility is broad and includes a wide range of domestic and non-domestic applicants.
Are U.S. colleges and universities eligible?
Yes. Public and private institutions of higher education are eligible.
Are nonprofit organizations eligible to apply?
Yes. Nonprofit organizations are eligible, including those with and without 501(c)(3) status.
Are for-profit organizations eligible?
Yes. For-profit organizations other than small businesses are eligible, and small businesses are also eligible.
Are government entities eligible applicants?
Yes. Eligible entities include many levels of government, including state, county, city/township, special district, and certain tribal governments.
Does the FOA include organizations that serve specific populations (for example, minority-serving institutions)?
Yes. The announcement explicitly includes institutions and organizations that serve specific populations, such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribal Colleges and Universities (TCCUs), and Alaska Native and Native Hawaiian Serving Institutions, among others.
Are foreign organizations or foreign institutions eligible to apply?
Yes. Foreign organizations and foreign institutions are eligible to apply.
Are foreign components of U.S. organizations allowed?
Yes. Foreign components of U.S. organizations are permitted consistent with NIH policy, allowing projects to incorporate international expertise or resources where justified.
Where can the full funding announcement be found?
The full announcement is available through the NIH grants guide at http://grants.nih.gov/grants/guide/pa-files/PAR-13-306.html.
Who was identified as the contact for access or linking issues related to the announcement?
Support for access or linking issues was routed through the NIH Office of Extramural Research (OER) webmaster.
What is the overall goal of this FOA?
The overall goal is to connect developmental biology to pharmacology and toxicology to improve mechanistic understanding of why drug effects and toxicities differ across pediatric life stages.
Browse more opportunities from the same category: Environment Health Income Security and Social Services
Next opportunity: Establishment of a Center of Journalism Excellence
Previous opportunity: Developmental Pharmacology and Toxicology Role of Ontogeny (R03)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 13 306
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 13 306) also looked into and applied for these:
| Funding Opportunity |
|---|
| Environmental Contributors to Autism Spectrum Disorders (R01) Apply for PAR 14 203 Funding Number: PAR 14 203 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: $400,000 |
| Environmental Contributors to Autism Spectrum Disorders (R21) Apply for PAR 14 202 Funding Number: PAR 14 202 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: $200,000 |
| Centers of Excellence on Environmental Health Disparities Research (P50) Apply for RFA ES 14 010 Funding Number: RFA ES 14 010 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: $1,000,000 |
| Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54) Apply for PAR 15 146 Funding Number: PAR 15 146 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Countermeasures Against Chemical Threats (CounterACT) Exploratory/Developmental Projects in Translational Research (R21) Apply for PAR 15 315 Funding Number: PAR 15 315 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Genetic Susceptibility and Variability of Human Structural Birth Defects (R01) Apply for PA 08 011 Funding Number: PA 08 011 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Developmental Pharmacology (R03) Apply for PAR 08 215 Funding Number: PAR 08 215 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Developmental Pharmacology (R21) Apply for PAR 08 216 Funding Number: PAR 08 216 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: $200,000 |
| Genetic and Genomic Analysis of Xenopus (R01) Apply for PAR 09 240 Funding Number: PAR 09 240 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Genetic and Genomic Analysis of Xenopus (R21) Apply for PAR 09 241 Funding Number: PAR 09 241 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: $200,000 |
| Countermeasures Against Chemical Threats (CounterACT) Cooperative Research Projects (U01) Apply for PAR 10 180 Funding Number: PAR 10 180 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54) Apply for PAR 10 181 Funding Number: PAR 10 181 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Developmental Pharmacology (R01) Apply for PAR 11 057 Funding Number: PAR 11 057 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: $499,999 |
| Developmental Pharmacology (R03) Apply for PAR 11 058 Funding Number: PAR 11 058 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: $50,000 |
| Developmental Pharmacology (R21) Apply for PAR 11 059 Funding Number: PAR 11 059 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: $200,000 |
| Countermeasures Against Chemical Threats (CounterACT) Cooperative Research Projects (U01) Apply for PAR 11 155 Funding Number: PAR 11 155 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: Case Dependent |
| Autism Centers of Excellence Centers (P50) Apply for RFA HD 12 195 Funding Number: RFA HD 12 195 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: $1,500,000 |
| Autism Centers of Excellence Networks (R01) Apply for RFA HD 12 196 Funding Number: RFA HD 12 196 Agency: National Institutes of Health Category: Environment Health Income Security and Social Services Funding Amount: $2,000,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 13 306", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.